{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:21:26Z","timestamp":1782220886056,"version":"3.54.5"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Ministry of Education Industry-University Cooperative Education Project","award":["No. 22087043124451"],"award-info":[{"award-number":["No. 22087043124451"]}]},{"DOI":"10.13039\/100016075","name":"Chinese Association of Integrative Medicine","doi-asserted-by":"publisher","award":["2019LY017"],"award-info":[{"award-number":["2019LY017"]}],"id":[{"id":"10.13039\/100016075","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Province Clinical Pharmacy Special Research Fund","award":["YS-2022-3-017"],"award-info":[{"award-number":["YS-2022-3-017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Fabry disease is characterized by an X sex chromosome gene mutation caused by \u03b1-galactosidase A deficiency, resulting in the accumulation of globotriaosylceramide and globotriaosylsphingosine in various organs, which induces end-organ lesions. In Fabry disease, enzymes with lost or decreased activity in the body are replaced by exogenous supplementation of normal-function \u03b1-galactosidase A. Currently, agalsidase \u03b1 and agalsidase \u03b2 are widely used for ERT therapy. However, this therapy has limitations such as high cost, short half-life, and production of neutralizing drug antibodies. The use of Migalastat as chaperone therapy has been approved in many countries, and it plays a therapeutic role by enhancing enzyme activity. However, companion therapy drugs are only suitable for patients with decreased enzyme activity, so the scope of their application is limited. In addition, there are several therapeutic drugs in development, including a new generation of ERT therapies, drugs resistant to neutralizing anti-drug antibody drugs, and substrate reduction therapy drugs. Due to the limitations of existing therapeutic drugs, researchers have begun to explore new therapeutic drugs for Fabry disease, so new pathogenic mechanisms and adjuvant therapeutic drugs have been continuously discovered, and the development of related drugs will contribute to disease control and treatment. This article summarizes the existing and potential drugs for treating Fabry disease to facilitate the selection of suitable and effective drugs for treatment.<\/jats:p>","DOI":"10.1186\/s13023-025-03646-y","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T03:03:49Z","timestamp":1741835029000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Status and frontiers of Fabre disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Wei","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqin","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyan","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-0840","authenticated-orcid":false,"given":"Jiana","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"issue":"1","key":"3646_CR1","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbadis.2010.09.007","volume":"1812","author":"MJ van Breemen","year":"2011","unstructured":"van Breemen MJ, et al. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta. 2011;1812(1):70\u20136.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"3646_CR2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ymgme.2014.01.014","volume":"111","author":"SM Sirrs","year":"2014","unstructured":"Sirrs SM, et al. Outcomes of patients treated through the Canadian Fabry disease initiative. Mol Genet Metab. 2014;111(4):499\u2013506.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"3646_CR3","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","volume":"55","author":"M Arends","year":"2018","unstructured":"Arends M, et al. Agalsidase Alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet. 2018;55(5):351\u20138.","journal-title":"J Med Genet"},{"key":"3646_CR4","doi-asserted-by":"crossref","unstructured":"Reisin R, Perrin A, Garcia-Pavia P. Time delays in the diagnosis and treatment of Fabry disease. Int J Clin Pract, 2017;71(1).","DOI":"10.1111\/ijcp.12914"},{"issue":"1","key":"3646_CR5","first-page":"91","volume":"130","author":"M Nowicki","year":"2020","unstructured":"Nowicki M, et al. Enzyme replacement therapy in Fabry disease in Poland: a position statement. Pol Arch Intern Med. 2020;130(1):91\u20137.","journal-title":"Pol Arch Intern Med"},{"issue":"7","key":"3646_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1056\/NEJM199302183280701","volume":"328","author":"JM Lusher","year":"1993","unstructured":"Lusher JM, et al. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate previously untreated patient study group. N Engl J Med. 1993;328(7):453\u20139.","journal-title":"N Engl J Med"},{"issue":"6","key":"3646_CR7","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.jaci.2017.12.1001","volume":"141","author":"M Lenders","year":"2018","unstructured":"Lenders M, et al. Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion. J Allergy Clin Immunol. 2018;141(6):2289\u2013e22927.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"3646_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ymgme.2012.12.005","volume":"108","author":"BE Smid","year":"2013","unstructured":"Smid BE, et al. A revised home treatment algorithm for Fabry disease: influence of antibody formation. Mol Genet Metab. 2013;108(2):132\u20137.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3646_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13023-023-02937-6","volume":"18","author":"A Linhart","year":"2023","unstructured":"Linhart A, et al. Safety and efficacy of pegunigalsidase Alfa in patients with Fabry disease who were previously treated with agalsidase Alfa: results from BRIDGE, a phase 3 open-label study. Orphanet J Rare Dis. 2023;18(1):332.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"3646_CR10","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, et al. Dose-Dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease. J Am Soc Nephrol. 2018;29(12):2879\u201389.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"3646_CR11","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/mt.2015.62","volume":"23","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Valenzano KJ. Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther. 2015;23(7):1138\u201348.","journal-title":"Mol Ther"},{"issue":"5","key":"3646_CR12","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","volume":"79","author":"EH McCafferty","year":"2019","unstructured":"McCafferty EH, Scott LJ. Migalastat: A review in Fabry disease. Drugs. 2019;79(5):543\u201354.","journal-title":"Drugs"},{"issue":"4","key":"3646_CR13","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with Migalastat. Genet Med. 2017;19(4):430\u20138.","journal-title":"Genet Med"},{"issue":"1","key":"3646_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/mt.2009.220","volume":"18","author":"R Khanna","year":"2010","unstructured":"Khanna R, et al. The Pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. Mol Ther. 2010;18(1):23\u201333.","journal-title":"Mol Ther"},{"issue":"8","key":"3646_CR15","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1136\/jmedgenet-2019-106005","volume":"56","author":"M Lenders","year":"2019","unstructured":"Lenders M, et al. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy. J Med Genet. 2019;56(8):548\u201356.","journal-title":"J Med Genet"},{"issue":"4","key":"3646_CR16","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ekir.2019.11.013","volume":"5","author":"A Felis","year":"2020","unstructured":"Felis A, et al. Current and investigational therapeutics for Fabry disease. Kidney Int Rep. 2020;5(4):407\u201313.","journal-title":"Kidney Int Rep"},{"issue":"4","key":"3646_CR17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, et al. Oral Pharmacological chaperone Migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288\u201396.","journal-title":"J Med Genet"},{"issue":"5","key":"3646_CR18","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1021\/acs.bioconjchem.8b00133","volume":"29","author":"I Ruderfer","year":"2018","unstructured":"Ruderfer I, et al. Development and analytical characterization of pegunigalsidase Alfa, a chemically Cross-Linked plant Recombinant human alpha-Galactosidase-A for treatment of Fabry disease. Bioconjug Chem. 2018;29(5):1630\u20139.","journal-title":"Bioconjug Chem"},{"issue":"12","key":"3646_CR19","doi-asserted-by":"publisher","first-page":"100968","DOI":"10.1016\/j.gim.2023.100968","volume":"25","author":"D Hughes","year":"2023","unstructured":"Hughes D, et al. Long-term safety and efficacy of pegunigalsidase Alfa: A multicenter 6-year study in adult patients with Fabry disease. Genet Med. 2023;25(12):100968.","journal-title":"Genet Med"},{"key":"3646_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.omtm.2022.07.009","volume":"26","author":"M Lenders","year":"2022","unstructured":"Lenders M, et al. Pre-existing anti-drug antibodies in Fabry disease show less affinity for pegunigalsidase Alfa. Mol Ther Methods Clin Dev. 2022;26:323\u201330.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"3646_CR21","doi-asserted-by":"crossref","unstructured":"Lenders M et al. Generation and characterization of a polyclonal human reference antibody to measure Anti-Drug antibody titers in patients with Fabry disease. Int J Mol Sci, 2021;22(5).","DOI":"10.3390\/ijms22052680"},{"issue":"3","key":"3646_CR22","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/joim.12647","volume":"282","author":"M Lenders","year":"2017","unstructured":"Lenders M, et al. Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease. J Intern Med. 2017;282(3):241\u201353.","journal-title":"J Intern Med"},{"issue":"2","key":"3646_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/gim.2012.110","volume":"15","author":"SG Banugaria","year":"2013","unstructured":"Banugaria SG, et al. Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease. Genet Med. 2013;15(2):123\u201331.","journal-title":"Genet Med"},{"issue":"4","key":"3646_CR24","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.ymgme.2012.01.019","volume":"105","author":"SG Banugaria","year":"2012","unstructured":"Banugaria SG, et al. Persistence of high sustained antibodies to enzyme replacement therapy despite extensive Immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells. Mol Genet Metab. 2012;105(4):677\u201380.","journal-title":"Mol Genet Metab"},{"key":"3646_CR25","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3389\/fimmu.2020.01000","volume":"11","author":"DC Julien","year":"2020","unstructured":"Julien DC, et al. Immune modulation for enzyme replacement therapy in A female patient with Hunter syndrome. Front Immunol. 2020;11:1000.","journal-title":"Front Immunol"},{"issue":"4","key":"3646_CR26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/cpt.790","volume":"103","author":"N Guerard","year":"2018","unstructured":"Guerard N, et al. Lucerastat, an Iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry disease on enzyme replacement. Clin Pharmacol Ther. 2018;103(4):703\u201311.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"3646_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13023-017-0565-9","volume":"12","author":"N Guerard","year":"2017","unstructured":"Guerard N, Morand O, Dingemanse J. Lucerastat, an Iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects. Orphanet J Rare Dis. 2017;12(1):9.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"3646_CR28","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1002\/jcph.944","volume":"57","author":"N Guerard","year":"2017","unstructured":"Guerard N, Zwingelstein C, Dingemanse J. Lucerastat, an Iminosugar for substrate reduction therapy: pharmacokinetics, tolerability, and safety in subjects with mild, moderate, and severe renal function impairment. J Clin Pharmacol. 2017;57(11):1425\u201331.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"3646_CR29","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s13023-020-01582-7","volume":"15","author":"MS Mueller","year":"2020","unstructured":"Mueller MS, et al. The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects. Orphanet J Rare Dis. 2020;15(1):303.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3646_CR30","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41467-021-21371-5","volume":"12","author":"A Khan","year":"2021","unstructured":"Khan A, et al. Lentivirus-mediated gene therapy for Fabry disease. Nat Commun. 2021;12(1):1178.","journal-title":"Nat Commun"},{"key":"3646_CR31","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.omtm.2020.07.002","volume":"18","author":"M Yasuda","year":"2020","unstructured":"Yasuda M, et al. AAV2\/6 gene therapy in a murine model of Fabry disease results in Supraphysiological enzyme activity and effective substrate reduction. Mol Ther Methods Clin Dev. 2020;18:607\u201319.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"3646_CR32","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41434-022-00381-y","volume":"30","author":"JM Jeyakumar","year":"2023","unstructured":"Jeyakumar JM, et al. Preclinical evaluation of FLT190, a liver-directed AAV gene therapy for Fabry disease. Gene Ther. 2023;30(6):487\u2013502.","journal-title":"Gene Ther"},{"issue":"10","key":"3646_CR33","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1089\/hum.2019.090","volume":"30","author":"P Martini","year":"2019","unstructured":"Martini P, Guey LT. A new era for rare genetic diseases: messenger RNA therapy. Hum Gene Ther. 2019;30(10):1180\u20139.","journal-title":"Hum Gene Ther"},{"issue":"4","key":"3646_CR34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","volume":"104","author":"X Zhu","year":"2019","unstructured":"Zhu X, et al. Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in Wild-Type mice, Fabry mouse model, and Wild-Type Non-human Primates. Am J Hum Genet. 2019;104(4):625\u201337.","journal-title":"Am J Hum Genet"},{"issue":"9","key":"3646_CR35","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ajhg.2023.07.013","volume":"110","author":"M Ter Huurne","year":"2023","unstructured":"Ter Huurne M, et al. GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individuals. Am J Hum Genet. 2023;110(9):1600\u20135.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"3646_CR36","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403\u201316.","journal-title":"N Engl J Med"},{"key":"3646_CR37","doi-asserted-by":"crossref","unstructured":"Chen Q, Davis KR. The potential of plants as a system for the development and production of human biologics. F1000Res. 2016;5(F1000 Faculty Rev):912.","DOI":"10.12688\/f1000research.8010.1"},{"issue":"4","key":"3646_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3109\/07388551.2013.793649","volume":"34","author":"AR Costa","year":"2014","unstructured":"Costa AR, et al. Glycosylation: impact, control and improvement during therapeutic protein production. Crit Rev Biotechnol. 2014;34(4):281\u201399.","journal-title":"Crit Rev Biotechnol"},{"issue":"2","key":"3646_CR39","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s10545-015-9886-9","volume":"39","author":"JS Shen","year":"2016","unstructured":"Shen JS, et al. Mannose receptor-mediated delivery of moss-made alpha-galactosidase A efficiently corrects enzyme deficiency in Fabry mice. J Inherit Metab Dis. 2016;39(2):293\u2013303.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"3646_CR40","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1681\/ASN.2019050497","volume":"31","author":"B Najafian","year":"2020","unstructured":"Najafian B, et al. Accumulation of globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss. J Am Soc Nephrol. 2020;31(4):865\u201375.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"3646_CR41","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.33594\/000000077","volume":"52","author":"F Braun","year":"2019","unstructured":"Braun F, et al. Enzyme replacement therapy clears Gb3 deposits from a podocyte cell culture model of Fabry disease but fails to restore altered cellular signaling. Cell Physiol Biochem. 2019;52(5):1139\u201350.","journal-title":"Cell Physiol Biochem"},{"key":"3646_CR42","doi-asserted-by":"crossref","unstructured":"Braun F et al. Accumulation of alpha-synuclein mediates podocyte injury in Fabry nephropathy. J Clin Invest, 2023;133(11).","DOI":"10.1681\/ASN.20223311S1514b"},{"issue":"1","key":"3646_CR43","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1186\/s12967-023-04475-y","volume":"21","author":"H Elsaid","year":"2023","unstructured":"Elsaid H, et al. Proteomic analysis unveils Gb3-independent alterations and mitochondrial dysfunction in a gla(-\/-) zebrafish model of Fabry disease. J Transl Med. 2023;21(1):591.","journal-title":"J Transl Med"},{"issue":"3","key":"3646_CR44","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3727\/096368916X694265","volume":"26","author":"WL Tseng","year":"2017","unstructured":"Tseng WL, et al. Imbalanced production of reactive oxygen species and mitochondrial antioxidant SOD2 in Fabry Disease-Specific human induced pluripotent stem Cell-Differentiated vascular endothelial cells. Cell Transpl. 2017;26(3):513\u201327.","journal-title":"Cell Transpl"},{"key":"3646_CR45","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.biochi.2016.09.011","volume":"130","author":"EM Kuech","year":"2016","unstructured":"Kuech EM, Brogden G, Naim HY. Alterations in membrane trafficking and pathophysiological implications in lysosomal storage disorders. Biochimie. 2016;130:152\u201362.","journal-title":"Biochimie"},{"key":"3646_CR46","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.imlet.2017.07.004","volume":"188","author":"D Rigante","year":"2017","unstructured":"Rigante D, et al. Overview of immune abnormalities in lysosomal storage disorders. Immunol Lett. 2017;188:79\u201385.","journal-title":"Immunol Lett"},{"issue":"1","key":"3646_CR47","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ymgme.2013.02.003","volume":"109","author":"PN De Francesco","year":"2013","unstructured":"De Francesco PN, et al. Fabry disease peripheral blood immune cells release inflammatory cytokines: role of globotriaosylceramide. Mol Genet Metab. 2013;109(1):93\u20139.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3646_CR48","doi-asserted-by":"publisher","first-page":"e54459","DOI":"10.1371\/journal.pone.0054459","volume":"8","author":"EH Schuchman","year":"2013","unstructured":"Schuchman EH, et al. Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS ONE. 2013;8(1):e54459.","journal-title":"PLoS ONE"},{"issue":"1","key":"3646_CR49","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0022-5347(05)64909-9","volume":"168","author":"PC Sadhukhan","year":"2002","unstructured":"Sadhukhan PC, et al. Sodium Pentosan polysulfate reduces urothelial responses to inflammatory stimuli via an indirect mechanism. J Urol. 2002;168(1):289\u201392.","journal-title":"J Urol"},{"issue":"2","key":"3646_CR50","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1365-2133.2007.08002.x","volume":"157","author":"CH Orteu","year":"2007","unstructured":"Orteu CH, et al. Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br J Dermatol. 2007;157(2):331\u20137.","journal-title":"Br J Dermatol"},{"issue":"7","key":"3646_CR51","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1093\/ndt\/gfp031","volume":"24","author":"R Schiffmann","year":"2009","unstructured":"Schiffmann R, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transpl. 2009;24(7):2102\u201311.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"3646_CR52","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.ymthe.2023.02.003","volume":"31","author":"JB Choi","year":"2023","unstructured":"Choi JB, et al. Fasudil alleviates the vascular endothelial dysfunction and several phenotypes of Fabry disease. Mol Ther. 2023;31(4):1002\u201316.","journal-title":"Mol Ther"},{"issue":"10","key":"3646_CR53","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s12276-021-00683-y","volume":"53","author":"JW Kim","year":"2021","unstructured":"Kim JW, et al. Human kidney organoids reveal the role of glutathione in Fabry disease. Exp Mol Med. 2021;53(10):1580\u201391.","journal-title":"Exp Mol Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03646-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03646-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03646-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T03:38:29Z","timestamp":1741837109000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03646-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3646"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03646-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"17 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"123"}}